Could less be more? Accounting for fractional-dose regimens and different number of vaccine doses when measuring the impact of the RTS, S/AS01E malaria vaccine.
Nelli WestercampLawrence Osei-TutuLode SchuermanSimon K KariukiAnne BollaertsCynthia K LeeAaron M SamuelsChristian OckenhouseDennis K BiiSamuel AdjeiMartina OnekoMarc LievensMaame Anima Attobrah SarfoCecilia AtienoAshura BakariTony SangMaame Fremah Kotoh-MorttyKephas OtienoFrançois RomanPatrick Boakye Yiadom BuabengYaw NtiamoahDaniel AnsongTsiri AgbenyegaOpokua Ofori-AnyinamPublished in: The Journal of infectious diseases (2024)
VE against clinical malaria was similar in all RTS, S groups. Vaccine impact accounting for full-dose equivalence suggests that using fractional-dose regimens could be a viable dose-sparing strategy. If borne out through trial end (M50), these observations underscore the means to reduce cost per regimen with a goal of maximising impact and optimising supply.